Key result
Nanoformulated ssRNA adjuvant with a coordinative amphiphile (CA-O, ~100 nm) improved activation of antigen-presenting cells and induction of neutralizing antibodies after single immunization.
Why the study?
Single-stranded RNAs are safe TLR7/8 agonist adjuvants, but their low stability prevents them from mounting sufficient immune responses.
Nanoformulation of ssRNA with a coordinative amphiphile (CA-O) improves its stability and efficacy as a vaccine adjuvant, potentially aiding in rapid vaccine development.
As agonists of TLR7/8, single‐stranded RNAs (ssRNAs) are safe and promising adjuvants that do not cause off‐target effects or innate immune overactivation. However, low stability prevents them from mounting sufficient immune responses. This study evaluates the adjuvant effects of ssRNA derived from the cricket paralysis virus intergenic region internal ribosome entry site, formulated as nanoparticles with a coordinative amphiphile, containing a zinc/dipicolylamine complex moiety as a coordinative phosphate binder, as a stabilizer for RNA‐based adjuvants. The nanoformulated ssRNA adjuvant was resistant to enzymatic degradation in vitro and in vivo, and that with a coordinative amphiphile bearing an oleyl group (CA‐O) was approximately 100 nm, promoted effective recognition, and improved activation of antigen‐presenting cells, leading to better induction of neutralizing antibodies following single immunization. Hence, CA‐O may increase the efficacy of ssRNA‐based adjuvants, proving useful to meet the urgent need for vaccines during pathogen outbreaks.
No takes yet. Share an insight, caveat, or question.
Park et al. (2020) studied Vaccine adjuvant development. Nanoformulated ssRNA adjuvant with a coordinative amphiphile (CA-O) was evaluated on Enzymatic degradation resistance, antigen-presenting cell activation, and neutralizing antibody induction. Nanoformulated ssRNA adjuvant with a coordinative amphiphile (CA-O, ~100 nm) improved activation of antigen-presenting cells and induction of neutralizing antibodies after single immunization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: